Fineline Cube

Follow:
14398 Articles
Sandoz Q3 2024 Sales Boosted by Biosimilars and Generics, Up 12% YOY
Company

Sandoz Q3 2024 Sales Boosted by Biosimilars and Generics, Up 12% YOY

Junshi Biosciences Reports Q3 2024 Financials with Revenue Growth and Narrowed Losses
Company

Junshi Biosciences Reports Q3 2024 Financials with Revenue Growth and Narrowed Losses

Chipsscreen Biosciences and Zhejiang Hisun Pharmaceutical End Strategic Partnership for Chiglitazar Launch
CompanyDeals

Chipsscreen Biosciences and Zhejiang Hisun Pharmaceutical End Strategic Partnership for Chiglitazar Launch

Eli Lilly Reports 20% YOY Revenue Growth in Q3 2024 Driven by Mounjaro and Zepbound
Company

Eli Lilly Reports 20% YOY Revenue Growth in Q3 2024 Driven by Mounjaro and Zepbound

AstraZeneca China President Leon Wang Involved in Chinese Investigation Amid Industry Probes
Company

AstraZeneca China President Leon Wang Involved in Chinese Investigation Amid Industry Probes

AbbVie's Allergan Aesthetics Launches Juvéderm VOLUX in China
CompanyDrug

AbbVie’s Allergan Aesthetics Launches Juvéderm VOLUX in China

Jiangsu Yuyue Medical Equipment Partners with TÜV SUD to Boost Medical Device Market Access
CompanyDeals

Jiangsu Yuyue Medical Equipment Partners with TÜV SUD to Boost Medical Device Market Access

GSK Reports Mixed Q3 2024 Results with 2% YOY Revenue Growth
Company

GSK Reports Mixed Q3 2024 Results with 2% YOY Revenue Growth

Allmed Medical Products to Establish Wholly Owned Subsidiary in Indonesia
CompanyDeals

Allmed Medical Products to Establish Wholly Owned Subsidiary in Indonesia

Sichuan Kelun-Biotech's Sacituzumab Tirumotecan Files for New Indication with China's NMPA
CompanyDrug

Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Files for New Indication with China’s NMPA

Akeso Biopharma Initiates Phase III Clinical Trial for PD-1/VEGF Bispecific Antibody Combination
CompanyDrug

Akeso Biopharma Initiates Phase III Clinical Trial for PD-1/VEGF Bispecific Antibody Combination

AbbVie Reports Q3 2024 Revenue Growth, Strength in Immunology and Neuroscience
Company

AbbVie Reports Q3 2024 Revenue Growth, Strength in Immunology and Neuroscience